Please ensure Javascript is enabled for purposes of website accessibility

Why BioCryst Pharmaceuticals Stock Is Popping Today

By Prosper Junior Bakiny - Updated Mar 1, 2021 at 2:19PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

This analyst sees significant upside ahead for the company.

What happened?

Shares of BioCryst Pharmaceuticals (BCRX 0.78%) are rising sharply today following bullish commentary from a Wall Street analyst. The biopharmaceutical company's stock was up by 9.2% as of 1:11 p.m. EST, after jumping by as much as 10.6% earlier on Monday. 

So what

Cowen analyst Ken Cacciatore initiated coverage on BioCryst stock with an outperform (buy) rating. Cacciatore also gave the stock a price target of $16. Shares of BioCryst Pharmaceuticals closed Friday's trading at $10.78, and they are at $11.89 as of this writing. In other words, the analyst's price target represents a significant upside on the stock, even accounting for today's rally. Why is Cacciatore so enthusiastic regarding BioCryst Pharmaceuticals' prospects? In a word: Orladeyo. 

Upward-bound graph on a dollar bill.

Image source: Getty Images.

Orladeyo is a once-daily pill to prevent hereditary angioedema attacks. It was approved by the Food and Drug Administration in December. BioCryst expects this medicine to generate peak sales of more than a half-billion dollars, and Cacciatore agrees with this assessment. The analyst believes that Orladeyo has great potential thanks to patients' preference for oral treatments. Cacciatore also thinks some of BioCryst's other programs add upside to the company's stock.

Now what

Should investors be as excited about BioCryst Pharmaceuticals as Cacciatore? On the one hand, there is no questioning Orladeyo's potential, but the company's future beyond this drug is a lot less certain. For that reason, I think it is worth it for long-term investors to keep an eye on this healthcare stock, but I wouldn't pull the trigger just yet. 

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

BioCryst Pharmaceuticals, Inc. Stock Quote
BioCryst Pharmaceuticals, Inc.
BCRX
$9.10 (0.78%) $0.07

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
331%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/20/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.